Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2010-10-22

Clinical Trial Update: Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 trial comparing olanzapine pamoate depot with oral olanzapine in outpatients with schizophrenia; results were posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ZYPREXA RELPREVV (olanzapine pamoate)
  • Zyprexa (olanzapine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2010-10-22